Ausiello Dennis A 4

What Happened
Dennis A. Ausiello, a director of Seres Therapeutics, Inc. (MCRB), received a grant/award of a derivative security covering 6,500 shares on July 8, 2026. The reported acquisition price is $0.00 (i.e., no cash paid at grant). This filing reflects an award (code A), not a purchase or sale.

Key Details

• Transaction date: July 8, 2026; Form 4 filed July 10, 2026.
• Transaction type: Award/Grant of a derivative security (Form 4 code A).
• Amount: 6,500 shares; reported price: $0.00 (no cash paid at grant).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The award vests and becomes exercisable on the earlier of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
• Filing timeliness: Form 4 was filed two days after the transaction date (within the standard two-business-day reporting window).

Context
This was a grant of a derivative award, not an option exercise or market sale. The award appears to be a time-based grant to a director with a vesting condition (see footnote). Such grants are commonly part of director compensation and do not by themselves indicate buying or selling of existing shares.